Welcome to our dedicated page for Ascentage Pharma Group International news (Ticker: AAPG), a resource for investors and traders seeking the latest updates and insights on Ascentage Pharma Group International stock.
Ascentage Pharma Group International reports recurring developments in cancer-focused drug commercialization and clinical development. The company is a global, commercial-stage integrated biopharmaceutical issuer with American depositary shares on Nasdaq and ordinary shares listed on HKEX. Its updates center on Olverembatinib, a third-generation BCR-ABL inhibitor approved in China, and Lisaftoclax, a China-developed Bcl-2 selective inhibitor, as well as oncology candidates such as Alrizomadlin, APG-2449, APG-5918 and APG-3288.
News from AAPG also covers clinical and preclinical data presented at oncology meetings, regulatory clearances for investigational studies, full-year financial results, commercial activity in China, pipeline progress in hematologic malignancies and solid tumors, and investor-conference communications.
Ascentage Pharma (NASDAQ:AAPG) published Phase Ib data for olverembatinib in Signal Transduction and Targeted Therapy reporting activity in SDH-deficient GIST. In 26 evaluable SDH-deficient patients the study showed an ORR 23.1%, CBR 84.6% (95% CI 65.1–95.6), and median PFS 25.7 months (95% CI 12.9–not reached) with median follow-up 14.5 months. Translational analyses identified lipid‑metabolism dysregulation and CD36 overexpression in SDH-deficient tumors and showed olverembatinib reduced CD36 and lipid uptake while inhibiting HIF, FGFR, and VEGFR pathways. Olverembatinib holds Breakthrough Therapy Designation from China CDE and a global Phase III trial (POLARIS-3, NCT06640361) is recruiting.
Ascentage Pharma (NASDAQ: AAPG) said its management will participate in three investor conferences in December 2025. Piper Sandler fireside chat is set for 9:00 AM ET on Dec 2, 2025. Evercore ISI HealthCONx fireside chat is set for 3:50 PM ET on Dec 3, 2025. The company will hold one-on-one meetings at the Citi 2025 Global Healthcare Conference on Dec 4, 2025. Investors can expect management commentary on company strategy and recent developments during these events.
Ascentage Pharma (NASDAQ: AAPG) announced that new clinical data for its orally available Bcl-2 inhibitor lisaftoclax (APG-2575) were selected for presentations at the 67th ASH Annual Meeting (Dec 6-9, 2025) including an oral report of a registrational Phase II in relapsed/refractory CLL/SLL and a poster of lisaftoclax plus azacitidine in myeloid malignancies.
Key disclosed results: in 72 evaluable R/R CLL/SLL patients ORR was 62.5%, median PFS 23.89 months, and peripheral blood MRD-negativity 21.8%. The drug is commercialized in China after NMPA approval for CLL/SLL.
Ascentage Pharma (NASDAQ: AAPG) will present multiple clinical and preclinical datasets at the 67th ASH Annual Meeting (Dec 6-9, 2025, Orlando and online). Key releases include the first dataset from POLARIS-1 (global Phase III; poster #1574) evaluating olverembatinib plus low-intensity chemotherapy in newly diagnosed Ph+ ALL and a reported MRD‑negative CR rate of 64.2% at end of induction (53 efficacy-evaluable patients).
Additional highlights: updated 4-year follow-up from a registrational randomized Phase II CML-CP study showing median EFS 21.22 vs 2.86 months (olverembatinib vs BAT; P < 0.001), second-line CP-CML updates, and multiple lisaftoclax and APG-5918 presentations.
Ascentage Pharma (NASDAQ: AAPG) announced that company management will participate in two investor events in November 2025.
Scheduled appearances: Goldman Sachs APAC Healthcare Corporate Day 2025 with one-on-one and group investor meetings on November 5, 2025, and a presentation at the Stifel 2025 Healthcare Conference on November 13, 2025 at 2:40 PM ET. The engagements provide investor access to management and updates on commercial and development progress.
Ascentage Pharma (NASDAQ: AAPG) said its management will participate in three investor conferences in October 2025.
Events and dates: Piper Sandler Virtual Oncology Symposium — fireside chat at 10:30 AM EDT on October 10, 2025; J.P. Morgan Global Healthcare Shanghai Conference — one-on-one and group investor meetings on October 16–17, 2025; BofA China Trailblazers Biotech Conference — one-on-one investor meetings on October 20–21, 2025.
Ascentage Pharma (NASDAQ: AAPG), a global commercial-stage biopharmaceutical company, has announced its participation in three major investor conferences in September 2025. The company will present at Citi's 2025 Biopharma Back to School (September 3), the Cantor Global Healthcare Conference 2025 (September 4), and the H.C. Wainwright 27th Annual Global Investment Conference (September 10).
Live webcasts for the Citi and Cantor events will be available on the company's investor relations website, with replays accessible for 30 days after the events.
Ascentage Pharma (NASDAQ: AAPG) reported strong H1 2025 financial results, with Olverembatinib sales surging 93% year-over-year to $30.3 million. The company achieved a significant milestone with the approval of Lisaftoclax, the first Bcl-2 inhibitor for CLL/SLL treatment in China.
Total revenue was $32.6 million, down 71.6% year-over-year due to prior year's one-time IP revenue. The company reported a net loss of $82.5 million ($0.24 per share). Cash position strengthened to $231.9 million, further bolstered by a $190.1 million top-up placement in July 2025.
Nine registrational trials are actively progressing, including three FDA-cleared studies. The company expanded its commercial reach with Olverembatinib now available in 782 DTP pharmacies and hospitals, representing a 17% increase year-over-year.
Ascentage Pharma (NASDAQ: AAPG) has received clearance from both the FDA and EMA to conduct the GLORA-4 study, a global Phase III registrational trial for lisaftoclax in combination with azacitidine. The study targets first-line treatment of higher-risk myelodysplastic syndrome (HR-MDS).
Lisaftoclax, a proprietary Bcl-2 inhibitor, is currently the only Bcl-2 inhibitor in Phase III trials for HR-MDS globally. Earlier studies showed promising results with a 75% overall response rate, significantly higher than current standard treatments. The multi-region, multi-center, randomized, double-blind trial is simultaneously enrolling patients in China, the U.S., and Europe.
If successful, lisaftoclax could become the first targeted therapy approved for HR-MDS first-line treatment since the introduction of hypomethylating agents, potentially addressing a significant unmet medical need in this field.
Ascentage Pharma (NASDAQ: AAPG), a global biopharmaceutical company focused on cancer treatments, will release its 2025 six-month interim results on August 20, 2025, at 7:00 PM EDT.
The company will host two investor webcasts with Q&A sessions: a Chinese language presentation on August 20 at 9:00 PM EDT, and an English language presentation on August 21 at 8:00 AM EDT. Both events will feature the company's management team and require advance registration.